The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential

Journal of Lipid Research

Volumn 49, Issue 5, 2008, Pages 954-960

  Zanotti, Ilaria ^a   Potì, Francesco ^a   Pedrelli, Matteo ^a   Favari, Elda ^a   Moleri, Elsa ^b   Franceschini, Guido ^b   Calabresi, Laura ^a,b   Bernini, Franco ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

ATP binding cassette A1; High density lipoprotein; Liver X receptor; Passive diffusion; Scavenger receptor class B type i

Indexed keywords

ABC TRANSPORTER A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; SCAVENGER RECEPTOR BI; ABC TRANSPORTER; CELL RECEPTOR; DNA BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPID; LIVER X RECEPTOR; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; CONTROLLED STUDY; DIFFUSION; FECES; IN VIVO STUDY; LIVER; MACROPHAGE; MALE; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; REVERSE CHOLESTEROL TRANSPORT; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CELL STRAIN COS1; CERCOPITHECUS; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HAPLORHINI; METABOLISM; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CERCOPITHECUS AETHIOPS; CHOLESTEROL; COS CELLS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HAPLORHINI; LIPIDS; LIPOPROTEINS, HDL; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONAMIDES;

EID: 50049130053     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700254-JLR200     Document Type: Article

References (32)

1. Lund, E. G., J. G. Menke, and C. P. Sparrow. 2003. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23: 1169-1177.
2. Millatt, L. J., V. Bocher, J. C. Fruchart, and B. Staels. 2003. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of atherosclerosis. Biochim. Biophys. Acta. 1631: 107-118.
3. Whitney, K. D., M. A. Watson, J. L. Collins, W. G. Benson, T. M. Stone, M. J. Numerick, T. K. Tippin, J. G. Wilson, D. A. Winegar, and S. A. Kliewer. 2002. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol. Endocrinol. 16: 1378-1385.
4. Schultz, J. R., H. Tu, A. Luk, J. J. Repa, J. C. Medina, L. Li, S. Schwendner, S. Wang, M. Thoolen, D. J. Mangelsdorf, et al. 2000. Role of LXRs in control of lipogenesis. Genes Dev. 14: 2831-2838.
5. Tangirala, R. K., E. D. Bischoff, S. B. Joseph, B. L. Wagner, R. Walczak, B. A. Laffitte, C. L. Daige, D. Thomas, R. A. Heyman, D. J. Mangelsdorf, et al. 2002. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA. 99: 11896-11901.
6. Repa, J. J., S. D. Turley, J. A. Lobaccaro, J. Medina, L. Li, K. Lustig, B. Shan, R. A. Heyman, J. M. Dietschy, and D. J. Mangelsdorf. 2000. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 289: 1524-1529.
7. Janowski, B. A., P. J. Willy, T. R. Devi, J. R. Falck, and D. J. Mangelsdorf. 1996. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 383: 728-731.
8. Terasaka, N., A. Hiroshima, T. Koieyama, N. Ubukata, Y. Morikawa, D. Nakai, and T. Inaba. 2003. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536: 6-11.
9. Joseph, S. B., E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. Laffitte, M. Chen, G. Noh, J. Goodman, G. N. Hagger, et al. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA. 99: 7604-7609.
10. Schuster,G.U.,P.Parini,L.Wang,S.Alberti,K.R.Steffensen,G.K. Hansson, B. Angelin, and J. A. Gustafsson. 2002. Accumulation of foam cells in liver X receptor-deficient mice. Circulation. 106:1147-1153.
11. Levin, N., E. D. Bischoff, C. L. Daige, D. Thomas, C. T. Vu, R. A. Heyman, R. K. Tangirala, and I. G. Schulman. 2005. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25: 135-142.
12. Barter, P. J., and K. A. Rye. 1996. Molecular mechanisms of reverse cholesterol transport. Curr. Opin. Lipidol. 7: 117-123.
13. Schwartz, K., R. M. Lawn, and D. P. Wade. 2000. ABC1 gene expression and apoA-I-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. Res. Commun. 274: 794-802.
14. Wang, N., M. Ranalletta, F. Matsuura, F. Peng, and A. R. Tall. 2006. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler. Thromb. Vasc. Biol. 26: 1310-1316.
15. Naik, S. U., X. Wang, J. S. Da Silva, M. Jaye, C. H. Macphee, M. P. Reilly, J. T. Billheimer, G. H. Rothblat, and D. J. Rader. 2006. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 113: 90-97.
16. Miao, B., S. Zondlo, S. Gibbs, D. Cromley, V. P. Hosagrahara, T. G. Kirchgessner, J. Billheimer, and R. Mukherjee. 2004. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J. Lipid Res. 45: 1410-1417.
17. Zhang, Y., I. Zanotti, M. P. Reilly, J. M. Glick, G. H. Rothblat, and D. J. Rader. 2003. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 108: 661-663.
18. Iverson, S. J., S. L. Lang, and M. H. Cooper. 2001. Comparison of the Bligh and Dyer and Folch methods for total lipid determination in a broad range of marine tissue. Lipids. 36: 1283-1287.
19. Nieland, T. J., M. Penman, L. Dori, M. Krieger, and T. Kirchhausen. 2002. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc. Natl. Acad. Sci. USA. 99: 15422-15427.
20. Connelly, M. A., S. M. Klein, S. Azhar, N. A. Abumrad, and D. L. Williams. 1999. Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake. J. Biol. Chem. 274: 41-47.
21. Zanotti, I., F. Poti, E. Favari, K. R. Steffensen, J. A. Gustafsson, and F. Bernini. 2006. Pitavastatin effect on ATP binding cassette A1- mediated lipid efflux from macrophages. Evidence for LXR- dependent and LXR-independent mechanisms of activation by cAMP. J. Pharmacol. Exp. Ther. 317: 1-7.
22. Favari, E., M. Lee, L. Calabresi, G. Franceschini, F. Zimetti, F. Bernini, and P. T. Kovanen. 2004. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I- mediated lipid efflux to high density lipoprotein. J. Biol. Chem. 279:9930-9936.
23. Cao, G., T. P. Beyer, X. P. Yang, R. J. Schmidt, Y. Zhang, W. R. Bensch, R. F. Kauffman, H. Gao, T. P. Ryan, Y. Liang, et al. 2002. Phospholipid transfer protein is regulated by liver X receptors in vivo. J. Biol. Chem. 277: 39561-39565.
24. Asztalos, B. F., M. de la Llera-Moya, G. E. Dallal, K. V. Horvath, E. J. Schaefer, and G. H. Rothblat. 2005. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J. Lipid Res. 46: 2246-2253.
25. Fournier, N., O. Francone, G. Rothblat, D. Goudouneche, M. Cambillau, G. Kellner-Weibel, P. Robinet, L. Royer, N. Moatti, A. Simon, et al. 2003. Enhanced efflux of cholesterol from ABCA1- expressing macrophages to serum from type IV hypertriglyceridemic subjects. Atherosclerosis. 171: 287-293.
26. Yancey, P. G., A. E. Bortnick, G. Kellner-Weibel, M. de la Llera-Moya, M. C. Phillips, and G. H. Rothblat. 2003. Importance of different pathways of cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 23: 712-719.
27. Cuchel, M., and D. J. Rader. 2006. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 113:2548-2555.
28. Kruit, J. K., T. Plosch, R. Havinga, R. Boverhof, P. H. Groot, A. K. Groen, and F. Kuipers. 2005. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology. 128: 147-156.
29. Duong, M., H. L. Collins, W. Jin, I. Zanotti, E. Favari, and G. H. Rothblat. 2006. Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. Arterioscler. Thromb. Vasc Biol. 26: 541-547.
30. Mulya, A., J. Y. Lee, A. K. Gebre, M. J. Thomas, P. L. Colvin, and J. S. Parks. 2007. Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler. Thromb. Vasc. Biol. 27: 1828-1836.
31. Yancey, P. G., M. de la Llera-Moya, S. Swarnakar, P. Monzo, S. M. Klein, M. A. Connelly, W. J. Johnson, D. L. Williams, and G. H. Rothblat. 2000. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem. 275: 36596-36604.
32. Grefhorst, A., B. M. Elzinga, P. J. Voshol, T. Plosch, T. Kok, V. W. Bloks, F. H. Van Der Sluijs, L. M. Havekes, J. A. Romijn, H. J. Verkade, et al. 2002. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 277: 34182-34190.